OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

Research-Grade
Biosimilar Antibodies

Benchmark assays, validate new antibody candidates, and de-risk preclinical programs with reproducible reference biologics—mapped to every major molecular target and ready to scale into in vivo studies.

Popular targets||||

Pembrolizumab Biosimilar (anti PD-1)

Pembrolizumab product image
FC analysis with biotinylated anti-PD-1 (Pembrolizumab Biosimilar) on HEK293T cells transfected with human PD-1 (blue) or HEK293T (red).

Magrolimab Biosimilar (anti CD47)

magrolimab product image
ELISA plate pre-coated with human CD47 protein (TP723931) can bind biotinylated anti-CD47 (Magrolimab Biosimilar) in a linear range of 0.061-1.606 ng/ml.

Cobolimab Biosimilar (anti TIM3)

Cobolimab product image
FC analysis with anti-TIM3 (Cobolimab Biosimilar) on HEK293 cells transfected with human TIM3 protein (blue) or HEK293 (red).

Enoblituzumab Biosimilar (anti B7-H3)

Enoblituzumab product image
ELISA plate pre-coated with human B7-H3 protein (TP723935) can bind biotinylated anti-B7-H3 (Enoblituzumab Biosimilar) in a linear range of 40–200 ng/mL.

Utomilumab Biosimilar (anti 4-1BB)

Enoblituzumab product image
ELISA plate pre-coated by human 4-1BB protein (TP723934) can bind anti-4-1BB (Utomilumab Biosimilar) in a linear range of 3.2-400 ng/ml.
255+
Research-grade biosimilar antibodies
180+
Molecular targets covered
13
Research areas
90
In vivo-grade biosimilars · low endotoxin for animal studies
In Vivo-Grade

Ready for in vivo? So are these biosimilars.

0.001 EU/µg
Endotoxin, as low as
>95%
Purity
Explore In Vivo-Grade Biosimilars →

Browse the portfolio

Explore Biosimilars by Research Area

Select a research area to see its molecular targets and the biosimilars available for each. Or search by target or biosimilar name to jump straight to a match.

View all Biosimilars →

Some targets are shared across indications (e.g. VEGF-A anti-angiogenics span oncology and ophthalmology); each is filed under its most-associated research area.

FAQ

Biosimilar antibodies: common questions